Clinical Trial

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The combination of surufatinib with neoadjuvant chemo-immunotherapy and definitive concurrent chemoradiotherapy represents a promising new therapeutic strategy that may further improve the prognosis of patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Therefore, we propose to conduct a prospective, single-arm, phase II clinical trial to evaluate the efficacy and safety of this regimen in patients with unresectable, locally advanced ESCC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-24.
Trial Details
NCT Number NCT07086469
Lead Sponsor Sun Yat-sen University
Conditions Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy, Chemoradiotherapy, Esophageal Squamous Cell Carcinoma
Enrollment 69 participants
Start Date 2025-07-20
Primary Completion 2029-07-19 (estimated)
Study Completion 2029-07-19 (estimated)
Updated on ClinicalTrials.gov 2025-11-17